Detalhe da pesquisa
1.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 376(16): 1551-1560, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28423301
2.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Lancet
; 389(10080): 1699-1709, 2017 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28411872
3.
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Ann Rheum Dis
; 77(9): 1295-1302, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945918
4.
Hyper IgM Syndrome: a Report from the USIDNET Registry.
J Clin Immunol
; 36(5): 490-501, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27189378
5.
Synthesis and Low Temperature Spectroscopic Observation of 1,3,5-Trioxane-2,4,6-Trione: The Cyclic Trimer of Carbon Dioxide.
J Org Chem
; 81(13): 5354-61, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27183100
6.
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
J Allergy Clin Immunol
; 136(1): 116-124.e7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25769911
7.
Online monitoring of biotransformations in high viscous multiphase systems by means of FT-IR and chemometrics.
Anal Chem
; 82(14): 6008-14, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20552985
8.
Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects.
Expert Opin Investig Drugs
; 28(5): 489-496, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30908082
9.
The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.
Medicine (Baltimore)
; 82(6): 373-84, 2003 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-14663287
10.
Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
J Clin Pharmacol
; 51(7): 1061-70, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20705951
11.
Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
Basic Clin Pharmacol Toxicol
; 108(3): 163-70, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20977679
12.
Multicategory Composite Least Squares Classifiers.
Stat Anal Data Min
; 3(4): 272-286, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21218128
13.
CD40 ligand-deficient T cells from X-linked hyper-IgM syndrome carriers have intrinsic priming capability.
J Immunol
; 168(3): 1473-8, 2002 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11801691
14.
Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy.
Pediatrics
; 113(2): e122-7, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14754981
15.
Progressive encephalopathy in primary immunodeficiency disease.
Clin Immunol
; 102(1): 1, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11781060